Bristol Myers BMY recently announced that it will acquire privately held biotechnology company Orbital Therapeutics for $1.5 ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Abstract: The deployment of Ka-band radar necessitates addressing increased losses due to rain and free-space propagation, in addition to achieving low sidelobe levels (SLL). Substrate integrated ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...

Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.

Between 2006 and 2017, the percentage of patients with CLL/SLL receiving first-line treatment within 3 years of diagnosis nearly doubled. Frailty significantly lowered the likelihood of initiating ...

Sonrotoclax achieved its primary endpoint of overall response rate in a phase 1/2 study for relapsed/refractory mantle cell lymphoma. The study involved 125 heavily pretreated patients, showing ...

Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an ...

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that ...

Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an ...